

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

April 2, 2019

Vimal Mehta Chief Executive Officer BioXcel Therapeutics, Inc. 555 Long Wharf Drive New Haven, CT 06511

Re: BioXcel Therapeutics, Inc.
Registration Statement on Form S-3
Filed April 1, 2019
File No. 333-230674

Dear Dr. Mehta:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Dorrie Yale at 202-551-8776 with any questions.

Sincerely,

Division of Corporation Finance Office of Healthcare & Insurance

cc: Stephen A. Cohen, Esq.